Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1907 1
1908 2
1909 1
1910 2
1911 2
1913 1
1916 1
1919 1
1921 1
1923 1
1924 1
1931 2
1966 1
1967 1
1978 1
1982 1
1984 1
1989 1
1990 1
1992 2
1993 1
1994 3
1995 2
1997 1
2001 1
2002 1
2003 1
2004 1
2005 1
2008 1
2011 1
2012 3
2015 1
2016 1
2017 4
2018 2
2019 3
2020 2
2021 7
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour JP, Menter A, Philipp S, Sofen H, Tyring S, Berner BR, Visvanathan S, Pamulapati C, Bennett N, Flack M, Scholl P, Padula SJ. Papp KA, et al. Among authors: flack m. N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017. N Engl J Med. 2017. PMID: 28423301 Free article. Clinical Trial.
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Among authors: flack m. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Reich K, et al. Among authors: flack m. Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Lancet. 2019. PMID: 31280967 Clinical Trial.
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A, Leonardi CL, Gooderham M, Papp KA, Philipp S, Wu JJ, Igarashi A, Flack M, Geng Z, Wu T, Camez A, Williams D, Langley RG. Blauvelt A, et al. Among authors: flack m. JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723. JAMA Dermatol. 2020. PMID: 32267471 Free PMC article. Clinical Trial.
NOTE ON SEA-SICKNESS.
Flack M. Flack M. Br Med J. 1931 Jan 31;1(3656):176-7. doi: 10.1136/bmj.1.3656.176. Br Med J. 1931. PMID: 20775981 Free PMC article. No abstract available.
Air-sickness and Sea-sickness: (Abridged).
Flack M. Flack M. Proc R Soc Med. 1931 Mar;24(5):635-41. Proc R Soc Med. 1931. PMID: 19988028 Free PMC article. No abstract available.
Problem Gambling: One for the Money…?
Flack M, Morris M. Flack M, et al. J Gambl Stud. 2015 Dec;31(4):1561-78. doi: 10.1007/s10899-014-9484-z. J Gambl Stud. 2015. PMID: 24986780
65 results